SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Jetstar to Charge for Overhead Cabin Bags From February 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
NEW YORK and LONDON, March 16, 2018 -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2017 on Wednesday, March 21, 2018 before the U.S. financial markets open. Following the release of the financial results, Akari Therapeutics management will conduct a conference call and webcast that morning at 8:30 a.m. Eastern Time (ET).
The call can be accessed by dialing (844) 461-9933 or (636) 812-6633 (international), and referencing conference ID 2096211. The conference call will also be webcast live over the Internet and can be accessed on the "Events & Presentations" page under the "Investors & Media" section of the Akari Therapeutics website, www.akaritx.com, prior to the event. A replay of the webcast will be available for at least 30 days following the call at www.akaritx.com.
About Akari Therapeutics
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression. Akari's lead drug candidate Coversin is a C5 complement inhibitor currently being evaluated in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). In addition to its C5 inhibitory activity, Coversin independently and specifically inhibits leukotriene B4 (LTB4) activity. Akari intends to evaluate Coversin in two conditions, the skin and eye diseases bullous pemphigoid and atopic keratoconjunctivitis, where the dual action of Coversin on both C5 and LTB4 may be beneficial. Akari is also developing other tick derived proteins, including long acting versions.
For more information
Investor Contact:
Peter Vozzo
Westwicke Partners
(443) 213-0505
[email protected]
Media Contact:
Mary-Jane Elliott / Sukaina Virji / Nicholas Brown
Consilium Strategic Communications
+44 (0)20 3709 5700
[email protected]
